Lilly reaffirms commitment to Alzheimer's disease
This article was originally published in Scrip
Executive Summary
Following news of its significant diabetes venture with Boehringer Ingelheim earlier this week (scripintelligence.com, 12 January 2010), Lilly's CEO Dr John Lechleiter was keen to highlight the firm's focus on Alzheimer's disease as also being key to its future growth, speaking at the JP Morgan healthcare in San Francisco conference this week.